PEXIVAS Trial

Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomised controlled trial.

Please use the buttons on the right to navigate our site and find out more about the PEXIVAS trial. For quick access to the most used sections of the site, please see the "Quick Links" section below.

What is PEXIVAS?

PEXIVAS is a multi-centre, international, open label, factorial design, randomised control trial in severe ANCA-associated vasculitis (AAV). Seven hundred participants will be randomised, 1:1, to receive adjunctive plasma exchange (PLEX) in addition to standard immunosuppressive therapy and glucocorticoids (GC) or standard immunosuppressive therapy and GC without PLEX. The same 700 patients will be randomised, 1:1, to receive reduced-dose GC taper or standard-dose GC taper. 

The first patient was randomised into PEXIVAS on Tuesday 8th June 2010 from Addenbrooke's Hospital, Cambridge, UK. Since then the trial has grown to encompass over 100 hundred centres around the world and recruited over 500 patients. The trial recruited 704 patients on 30th September 2016 and is scheduled to end in September 2017.